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Myeloid-derived suppressor cells (MDSCs) are powerful immunomodulatory cells that in mice play a role in
infectious and inﬂammatory disorders, including acute graft-versus-host disease (GVHD) after allogeneic
hematopoietic stem cell transplantation. Their relevance in clinical acute GVHD is poorly known. We analyzed
whether granulocyte colony-stimulating factor (G-CSF) administration, used to mobilize hematopoietic stem
cells, affected the frequency of MDSCs in the peripheral blood stem cell grafts of 60 unrelated donors. In
addition, we evaluated whether the MDSC content in the peripheral blood stem cell grafts affected the
occurrence of acute GVHD in patients undergoing unrelated donor allogeneic stem cell transplantation.
Systemic treatment with G-CSF induces an expansion of myeloid cells displaying the phenotype of monocytic
MDSCs (Linlow/negHLA-DRCD11bþCD33þCD14þ) with the ability to suppress alloreactive T cells in vitro,
therefore meeting the deﬁnition of MDSCs. Monocytic MDSC dose was the only graft parameter to predict
acute GVHD. The cumulative incidence of acute GVHD at 180 days after transplantation for recipients
receiving monocytic MDSC doses below and above the median was 63% and 22%, respectively (P ¼ .02). The
number of monocytic MDSCs infused did not impact the relapse rate or the transplant-related mortality rate
(P > .05). Although further prospective studies involving larger sample size are needed to validate the exact
monocytic MDSC graft dose that protects from acute GVHD, our results strongly suggest the modulation of G-
CSF might be used to affect monocytic MDSCs graft cell doses for prevention of acute GVHD.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Myeloid-derived suppressor cells (MDSCs) consist of a
group of morphologically and functionally heterogeneous
population of myeloid progenitor cells, dendritic cells,
and immature myeloid cells that suppress immune re-
sponses in vivo and in vitro [1]. In mice, the expression of the
Gr-1 antigen (Ly6C/Ly6G) and cellular morphology have been
used to characterize 2 major populations of MDSCs: granu-
locytic MDSCs expressing CD11bþLy6GþLy6CintCD115low
and monocytic MDSCs (M-MDSCs) expressing CD11bþ-
Ly6G-Ly6CþCD115þ [2,3].edgments on page 2055.
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ty for Blood and Marrow Transplantation.Human MDSC phenotype is less deﬁned. Both granulo-
cytic and monocytic human MDSCs express CD33, CD11b,
and low/negative levels of HLA-DR with variable expression
of CD15 (granulocyte MDSC) and CD14 (M-MDSC). These
populations are able to inhibit alloreactive responses
mediated by T lymphocytes and natural killer (NK) cells
through a variety of mechanisms that include L-arginine
depletion by arginase 1 and the inducible nitric oxidase,
generation of reactive oxygen species, release of trans-
forming growth factor-b and IL-10, cysteine sequestration,
and regulatory T cell (Treg) induction [1,4]. In physiological
situations, immature myeloid cells mature into dendritic
cells, macrophages, and neutrophils/granulocytes upon
entering the peripheral blood. In pathological conditions,
growth factors boost immature myeloid cell expansion and
interfere with their normal differentiation, inducing the
MDSC phenotype [1].
Table 1
Patient, Graft, and Transplant Characteristics
Characteristic Value
Number of patients 60
Number of donors 60
Median patient age at transplant, yr (range) 44 (18-67)
Median donor age, yr (range) 34 (20-43)
Median follow-up, mo (range) 17 (13 days to 53 mo)
Diagnosis
Acute myeloid leukemia 6 (10%)
Non-Hodgkin lymphoma 21 (35%)
Multiple myeloma 12 (20%)
Hodgkin disease 17 (28%)
Chronic lymphocytic leukemia 4 (6%)
Male/female patients 39/21 (65%/35%)
Male/female donors 46/14 (77%/23%)
HLA disparity
10/10 alleles 30 (50%)
9/10 alleles 17 (28%)
8/10 alleles 13 (22%)
Conditioning regimen
Cyclophosphamide (100 mg/kg) þ
thiotepa (10 mg/kg)
19 (32%)
Cyclophosphamide (60 mg/kg)
thiotepa (10 mg/kg) þ ﬂudarabine
(60 mg/m2)
17 (28%)
Cyclophosphamide (60 mg/kg) þ thiotepa
(10 mg/kg) þ ﬂudarabine (120 mg/m2)
þ total body irradiation (2 Gy)
2 (3%)
Fludarabine (90 mg/m2) þ melphalan
(100-140 mg/m2)
15 (25%)
Fludarabine (90 mg/m2) þ total body
irradiation (2 Gy)
4 (7%)
Fludarabine (150 mg/m2) þ busulfan
(.8 mg/kg)
3 (5%)
GVHD prophylaxis
Methotrexate with cyclosporine 52 (87%)
Mycophenolate mofetil with cyclosporine 8 (13%)
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patients in which they are responsible of immune escape
phenomena [5,6], there has been growing interest in un-
derstanding their role in infectious and inﬂammatory dis-
orders including acute graft-versus-host disease (aGVHD)
after allogeneic hematopoietic stem cell transplantation
(allo-HSCT). GVHD represents 1 of the most frequent
complications of allo-HSCT and remains a major cause of
morbidity and mortality related to this therapy. Advances
in aGVHD prevention and treatment, new conditioning
regimens, and better donor selection have improved the
outcomes of patients undergoing allo-HSCT [7].
In preclinical mouse models, cotransplantation of func-
tional MDSCs in a fully MHC-mismatched mouse model of
HSCT led to a decrease in aGVHD severity and mortality
without abrogating the graft-versus-tumor (GVT) effect [8].
These cells were obtained in vitro through exposure of bone
marrow cells to granulocyte-macrophage colony-stimulating
factor (GM-CSF), granulocyte colony-stimulating factor (G-
CSF), and IL-13. Additional evidence to support the involve-
ment of MDSCs in aGVHD was shown in patients in which a
speciﬁc subset of MDSC expressing the monocytic CD14
markerand lowlevelsor lackof theantigenpresentingHLA-DR
molecules (CD14þHLA-DRlow/neg cells) accumulate after allo-
HSCT [9]. These cells suppressed the proliferation of autolo-
gous T cells and their frequency correlated signiﬁcantly with
the serum levelsofG-CSF,which in fact has beendemonstrated
to induce T cellesuppressive CD14þmyeloid cells [10].
Based on these ﬁndings, the aim of the present study was
ﬁrst to investigate the effect of G-CSF administration, used to
mobilize hematopoietic stem cells, on the frequency ofCD14þ M-MDSCs (Linlow/negHLA-DRCD11bþCD33þCD14þ)
in the peripheral blood stem cell (PBSC) grafts of 60 unre-
lated donors and second to search for a correlation between
the number of M-MDSCs infused with the graft and the
incidence of aGVHD.METHODS
Patients and Donors
All patients were transplanted from their respective unrelated donors at
the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan. Written
informed consent was obtained, and the institutional review board
approved the study (Comitato Etico Indipendente, Fondazione IRCCS Istituto
Nazionale dei Tumori, Milan, protocol number INT45/12; 4/24/2012). Pa-
tients, donors, and transplant characteristics are described in Table 1. Stem
cell mobilization, collection, treatment, and storage were done according to
the standard operating procedures approved by the Joint Accreditation
Committee of International Society for Cellular Therapy Europe and the
European Group for Blood and Marrow Transplantation.
Donors were mainly young men (46 men versus 14 women; median age
34 [range, 20 to 43]) treated with G-CSF [ﬁlgrastim] 10 mg/kg/day for 5 days
before leukoapheresis. All patients received allo-HSCT for hematologic ma-
lignancies (Table 1). Three patients (5%) received ﬂudarabine (150 mg/m2)
and busulfan (.8 mg/kg), 4 patients (7%) received ﬂudarabine (90 mg/m2)
combined with low-dose total body irradiation (2 Gy), and all other patients
received a conditioning regimen based either on ﬂudarabine (90 mg/m2) and
melphalan (100 to 140 mg/m2; 15 patients [25%]) or thiotepa (10 mg/kg) and
cyclophosphamide (60 to 100 mg/m2; 38 patients [63%]) with or without
ﬂudarabine (60 to 120 mg/m2) (Table 1). GVHD prophylaxis consisted of
cyclosporine and short-coursemethotrexate (n¼ 52 [87%]) ormycophenolate
mofetil (n ¼ 8 [13%]). Diagnosis and clinical grading of aGVHD were per-
formed using the international standard criteria [7]. Sixty age-matched
healthy control subjects were also included in the study.Chimerism Analysis
Chimerism analysis was carried out as previously described [11] on
peripheral blood collected monthly after transplantation.Flow Cytometry and Graft Content Analysis
Sixty PBSC grafts collected by apheresis procedure were analyzed by
ﬂow cytometry at the moment of transplantation, and the number of CD34þ
hematopoietic stem cells, total CD3þ lymphocytes, CD4þ helper and CD8þ
cytotoxic T cells, CD19þ B lymphocytes, and CD16þ-CD56þ NK cells was
determined using Trucount tubes containing ﬂuorescent beads as an
internal standard (BD Biosciences, San Jose, CA) [12] and the appropriate
monoclonal antibodies (Supplemental Table 1). M-MDSCs (deﬁned as Linlow/
negHLA-DRCD11bþCD33þCD14þ), Tregs (CD4þCD25þCD127-FoxP3þ), and
invariant NK T cells (iNKT; CD3þTCRVa24-Ja18þTCRVb11þCD4þ and
CD3þTCRVa24-Ja18þTCRVb11þCD4-) were analyzed by ﬂow cytometry
retrospectively on frozen samples [6,13] using the listed ﬂuorochrome-
coupled monoclonal antibodies (Supplementary Table 1). Staining of cells
was performed at 4C for 20 minutes in the dark in ﬂuorescent activated cell
sorter staining buffer (1 PBS supplemented with 2% FBS). For intracellular
FoxP3 staining, after extracellular staining, cells were permeabilized and
stained according tomanufacturer instructions (FoxP3 Staining Kit; Miltenyi
Biotec, Bergisch-Gladbach, Germany). Cell acquisition and analysis were
performed on a FacsCalibur cytometer using CellQuest software (BD Bio-
sciences) or on a MACS Quant cytometer using MACS Quantify Software
(Miltenyi Biotec). A minimum of 5  105 events were collected for accurate
data acquisition.Immunomagnetic Cell Separation
Immunomagnetic separations were performed using Automacs Pro
Separator (Miltenyi Biotec). For CD3þ lymphocyte isolation, peripheral blood
mononuclear cells isolated by Ficoll density gradient (Lymphoprep; Axis-
Shield, Oslo, Norway) were suspended in separation buffer (PBS supple-
mented with .5% BSA) and incubated with anti-CD3 microbeads (Miltenyi
Biotec) for 15 minutes at 4C. After washing, cells were separated through a
double-column positive selection. For M-MDSC enrichment, PBSCs were
ﬁrst incubated with anti-HLA-DR microbeads (Miltenyi Biotec) to deplete
HLA-DR positive cells. Thereafter, CD33þ cells were separated using anti-
CD33 microbeads (Miltenyi Biotec). Separations were performed according
to manufacturer instructions. Purity of the selected populations was eval-
uated by ﬂow cytometry, demonstrating an efﬁciency of separation above
90% in all experiments.
Figure 1. G-CSF treatment of HSCT donors induces an increase in the fre-
quencies of circulating M-MDSCs in respect to healthy nontreated volunteers
as assessed by ﬂow cytometric evaluation of Linlow/neg HLA-DR CD11bþ
CD33þ CD14þ (P ¼ .0002). Bars represent median values, whereas whiskers
represent minimum and maximum.
Figure 2. In vitro co-culture of immunomagnetic selected CD3 T lymphocytes
isolated from peripheral blood of HSCT donors and M-MDSCs selected through
a double-step immunomagnetic separation. PBSC graft cells were ﬁrst
depleted of HLA-DRþ cells, and thereafter myeloid cells expressing the CD33
antigenwere enriched through positive selection. Purity of all populations was
assessed by ﬂow cytometry, demonstrating an efﬁciency of separation of more
than 90% in all experiments. CD3þ lymphocytes were stimulated with CD2/
CD3/CD28 microbeads with or without different ratios of M-MDSCs (1:1 or
1:5). Cells were also plated without microbeads as negative control. Immu-
nosuppressive properties of M-MDSCs were assessed by ﬂow cytometric
analysis of the surface activation markers CD25 and CD137. Co-culture ex-
periments demonstrate the ability M-MDSCs to suppress T cell activation in a
dose-dependent manner on both CD4þ helper T cells and CD8þ cytotoxic T
cells. Experiments were carried out in triplicate.
A. Vendramin et al. / Biol Blood Marrow Transplant 20 (2014) 2049e2055 2051CD3þ/MDSC Co-Culture
Selected CD3þ lymphocytes and MDSCs were co-cultured in RPMI 1640
(Sigma-Aldrich, St. Louis, MO) supplemented with 10% FBS, penicillin/
streptomycin, and 2mM L-glutamine at a ratio of 1:1 and 1:5 in the presence
of anti-CD2/CD3/CD28 biotin beads according to manufacturer instructions
(Miltenyi Biotec). Three to 5 105 T lymphocytes were plated in triplicate in
24-well ﬂat bottom plates. As positive control, lymphocytes were stimulated
in the absence of MDSCs; as negative control, CD3þ cells and MDSCs were
incubated in the absence of stimuli. After 4 days of culture, cells were har-
vested and expression of the surface activation markers CD25 and CD137
[11,14] was evaluated through ﬂow cytometry.Statistical Analysis
Class comparisons for clinical variables and graft cell subset doses
infused were made with the Mann-Whitney test or Fisher’s exact test for
categorical variables. Probability of aGVHD was calculated with the cumu-
lative incidence procedure, with relapse and death without aGVHD within
180 days as competing events. Survival curves were plotted using Kaplan-
Meier estimates and compared by log-rank analysis. All analysis were car-
ried out using GraphPad Prism 5.0 (GraphPad, San Diego, CA) and R (The R
Project [http://www.r-project.org/], packages “ROCR” and “cmprsk”).
Multivariate analysis was performed by ﬁtting a logistic regression model
with a backward selection procedure using SPSS version 20. P < .05 was
deemed statistically signiﬁcant.RESULTS
G-CSF Induces an Increase of the M-MDSCs Population in
Peripheral Blood of Mobilized PBSC Donor
We ﬁrst tested the hypothesis that G-CSF administration,
routinely used for the mobilization of CD34þ stem cells of
healthy PBSC donors, may induce an in vivo expansion of
MDSCs. Speciﬁcally, we analyzed the phenotype and the
frequency of MDSCs in the peripheral blood of PBSC donors
(n ¼ 60) and in age-matched healthy control subjects
(n ¼ 60). In line with previous reports from patients treated
with G-CSF or GM-CSF for autologous PBSC transplantation
[10,15], we detected an expansion of a monocytic CD14þ
myeloid population displaying the phenotype of M-MDSCs
(Linlow/negHLA-DRCD11bþCD33þCD14þ; Supplemental
Figure 1). There was a signiﬁcant increase in the number of
circulating M-MDSCs in the peripheral blood of the G-
CSFetreated donors compared with the age-matched
healthy untreated subjects (3.36% and 1.21% of total CD45þ
cells, respectively, P < .001, Mann-Whitney t-test) (Figure 1).
Further analysis demonstrated that G-CSF treatment resultedin a variable expansion of M-MDSC within the donor popu-
lation analyzed (.8% to 7.8% of total CD45þ cells). There was
no signiﬁcant correlation between the number of circulating
M-MDSCs cells and the age or sex of the PBSC donors
(P > .05; Fisher’s exact t-test; median age 34 years [range, 20
to 43]).Immune-Suppressive Activity of G-CSFeInduced
M-MDSCs
We analyzed whether the Linlow/negHLA-DRCD11bþ-
CD33þCD14þ M-MDSC population identiﬁed in the periph-
eral blood of PBSC donors exerted an immune-suppressive
activity in vitro. M-MDSCs and autologous CD3þ T cells
were isolated from the peripheral blood of G-CSFetreated
donors (n ¼ 10) using immunomagnetic selection strategies
(see Methods). Highly puriﬁed Linlow/negHLA-DRCD11bþ-
CD33þCD14þ cells were recovered (>90% as assessed by ﬂow
cytometry) and thereafter co-cultured for 4 days with
autologous T cells in the presence of T cell stimulators (IL-2
and anti-CD2/CD3/CD28 Abs).
Flow cytometric analysis demonstrated that G-CSFein-
duced M-MDSCs, signiﬁcantly suppressed T cell responses as
demonstrated by the analysis of the expression of CD25 and
CD137 activation markers on CD4þ and CD8þ T cells. A sig-
niﬁcant decrease in CD25 and CD137 expression levels was
detected both on CD3þCD4þ helper and CD3þCD8þ cytotoxic
lymphocytes (P < .05, Mann-Whitney t-test) (Figure 2).Patients and aGVHD Incidence
Sixty patients received G-CSFemobilized PBSC donor
grafts for hematological malignancies. Most patients had
lymphoma (n ¼ 42; 70%) and myeloma (n ¼ 12; 20%),
whereas 6 patients had acute myeloid leukemia (n ¼ 6; 10%)
(Table 1). All patients reached a full donor chimerism before
day 30 after transplantation as assessed by analysis of vari-
able number of tandem repeats on peripheral blood. Platelet
recovery (count >20,000/mL) was achieved at a median of
day 9 post-transplantation (range, 3 to 20), whereas neu-
trophils reached values great than 500/mL on day 11 (range, 3
Figure 3. Probabilities of aGVHD were calculated with the cumulative inci-
dence procedure, with relapse and death without aGVHD within 180 days as
competing events (48%).
Table 2
PBSC Graft Content of 60 G-CSFeTreated Donors Analyzed by Flow
Cytometry
Mean
(106/kg
body
weight)
SD Median
(106/kg
body
weight)
Range Mann-
Whitney
Test P
CD34 7.26 3.33 6.7 3.3-14.9 .52
CD45 1041.18 416.51 978.4 423.8-2029.5 .83
CD3 284.56 111.67 261 130-546 .47
CD4 179.73 84.59 153.7 59.7-427.7 .43
CD8 96.04 39.56 86.1 46-178.6 .94
CD19 67.05 43.25 57.7 6.4-232.4 .58
CD16-56 39.59 18.57 38 6.35-81.7 .22
Tregs 3.27 1.16 3.3 1.48-6.15 .90
iNKT CD4þ .42 .35 .3 .0001-1.29 .30
iNKT CD4- .32 .30 .2 .0001-1.09 .09
M-MDSCs 39.13 29.98 33.6 3.35-159.99 .02
SD indicates standard deviation.
Mann-Whitney t-test was performed to assess possible associations be-
tween quantity of cells infused and aGVHD onset. The only population
signiﬁcantly associated with aGVHDwas Linlow/neg HLA-DR CD11bþ CD33þ
CD14þ, M-MDSCs. P values are referred to Mann-Whitney test performed
comparing patients developing aGVHD versus those not experiencing the
complication.
Figure 4. Box plots showing the absolute number of infused M-MDSCs with
respect to aGVHD. Signiﬁcantly lower quantity of M-MDSC/kg body weight
were infused in patients who developed aGVHD with respect to those who did
not (median 28.5  106/kg versus 49.4  106/kg total CD45þ cells, Mann-
Whitney t-test P ¼ .02). Bars represent median values, whereas whiskers
represent minimum and maximum.
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not shown).
The cumulative incidence of aGVHD at 180 days after
transplantation for the 60 patients receiving a G-CSFemo-
bilized PBSC allograft from unrelated donors was 48%
(Figure 3). Overall, 2 patients (5%) developed grade IV
aGVHD, 3 patients (10%) developed grade III aGVHD, 10 pa-
tients (38%) had grade II aGVHD, and 13 patients (47%)
developed grade I aGVHD. All patients developed cutaneous
aGVHD, whereas 4 patients (12.5%) developed concomitant
hepatic, 3 (10%) intestinal, 2 (5%) gastric, and 2 (5%) multi-
organ aGVHD. Nine patients developed chronic GVHD
115 days after transplantation (n ¼ 9; 15%).
Several clinical variables have been shown to correlate
with aGVHD onset, particularly, donorerecipient sex
mismatch, donor and patient age, the degree of HLA in-
compatibility, and the type of conditioning regimen [16-18].
In our cohort of patients, none of these parameters was
signiﬁcantly associated with the development of aGVHD
(P > .05, Fisher’s exact t-test, Supplementary Table 2). Me-
dian follow-up was 17 month (range, 13 days to 53 months).
Incidence of relapse was 20% (12/60), whereas transplant-
related mortality was 12% (7/60).
PBSC Graft Content and aGVHD
The PBSC graft content of different cell population pre-
viously shown to impact on aGVHD [13,19-23] was analyzed.
Enumeration of total T cells, B cells, NK cells, CD4 and CD8 T
cells, Treg lymphocytes (CD4þCD25þCD127-FoxP3þ), and
iNKT (CD3þTCRVa24-Ja18þTCRVb11þCD4þ and
CD3þTCRVa24-Ja18þTCRVb11þCD4-) was performed using
ﬂow cytometry. The absolute doses of the graft cell pop-
ulations infused to patients at the time of PBSC trans-
plantation are shown in Table 2. No signiﬁcant correlation
was found between the number of cells infused and aGVHD
development (P > .05, Mann-Whitney t-test). In contrast
with recent reports [13], in our study analysis failed to reveal
a correlation between either the total iNKT population or the
2 subsets CD4þ and CD4- (P > .05, Mann-Whitney t-test) and
aGVHD. Cumulative incidence of aGVHD at 180 days aftertransplantation for recipients receiving cell doses below and
above the median were 45% and 60%, respectively (P ¼ .73,
Gray’s test), for CD4þ iNKT and 50% and 55%, respectively
(P ¼ .65, Gray’s test), for CD4- iNKT. Similarly, there was no
association between the number of Tregs infused and
aGVHD. At 180 days after transplantation, patients receiving
Treg doses below and above the median had a cumulative
incidence of 55% and 44%, respectively (P ¼ .58 Gray’s test).
Because the main feature of M-MDSCs that distinguishes
them from the other cellular components is their ability to
suppress T cells responses, we speculated that the M-MDSC
graft content could have an impact on the incidence of
aGVHD. The hypothesis that the M-MDSC graft content may
be related to aGVHD development comes from mouse ex-
periments indicating that adding functional MDSCs to donor
grafts alleviates GVHD while preserving the GVT effect [8].
Indeed, class comparison analysis demonstrated that higher
doses of M-MDSCs in the graft are associated with a minor
risk of developing aGVHD (P ¼ .02, Mann-Whitney t-test,
Figure 4). Patients developing aGVHD received a median
dose of 28.5  106 cells/kg body weight (range, 3.35 to 94.2),
whereas patients not developing the complication received a
Figure 6. The dose of 37  106 M-MDSC/kg body weight is associated with the
best combination of sensitivity and speciﬁcity. Receiver-operating character-
istic curve displaying the false-positive rate versus the true-positive rate for
every possible dose of M-MDSCs infused (area under the curve [AUC] .71).
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159.9). In addition, a signiﬁcant correlation between the
number of M-MDSCs infused at the time of transplantation
and the severity of aGVHD was found (median 22.64 M-
MDSC/kg body weight in grades II to IV aGVHD versus 39.93
M-MDSC/kg body weight in grades 0 to I aGVHD, Mann-
Whitney t-test P ¼ .017).
The cumulative incidence of aGVHD at 180 days after HSCT
for recipients receiving cell doses below and above the me-
dian for total M-MDSCs was 63% and 22%, respectively
(P ¼ .02, Gray’s test, Figure 5). No correlation was found
between number of M-MDSCs infused and incidence of
chronic GVHD (P > .05, Mann-Whitney t-test). Our results
suggest a role of donor M-MDSCs in the early post-transplant
immune suppression that might be involved in regulating
alloreactive T cells responsible of aGVHD. Notably, the number
of M-MDSCs infused did not impact the relapse rate or the
transplant-related mortality rate (P > .05, Mann-Whitney t-
test). Patients receiving doses above and below the median
quantity of M-MDSCs displayed the same 1-year overall sur-
vival and event free survival rates (P > .05; log-rank test),
suggesting this population does not alter hematopoietic
reconstitution and immune surveillance after transplantation.
The Graft Cell Dose of Linlow/negHLA-DRCD11bþCD33þ
CD14þ Predicts for the Occurrence of aGVHD
To identify a dose of infused M-MDSCs able to exert a
protective effect on aGvHD, data were analyzed by a receiver
operating characteristic (ROC) curve model (Figure 6).
Sensitivity and speciﬁcity were plotted in a ROC curve, a plot
of the false-positive rate and true-positive rate for every
possible dose of M-MDSCs infused. The graft dose of 37,13 
106 M-MDSCs cells/kg of body weight is able to discriminate
patients developing aGVHD after MUD allo-HSCT with a
speciﬁcity of 84,2% and a sensitivity of 76,6% (Figure 6, AUC
0.71). Furthermore, a multivariate regression analysis
adjusted for variables with P-values<0.5 in class comparison
analysis was performed. Taking into account MDSC cell doses
below or above the cut-off value identiﬁed by the ROC
analysis, multivariate analysis conﬁrmed that the number ofFigure 5. Cumulative incidence of aGVHD at 180 days after unrelated HSCT in
patients receiving below (solid line) versus above (dashed line) the median
dose of M-MDSCs (64% and 22%, respectively, Gray’s test P ¼ .02).M-MDSC/kg of body weight is the only independent factor
associated with the occurrence of aGVHD (Table 3).DISCUSSION
Recent experimental evidence support the view that
MDSCs have an immunoregulatory role in allo-HSCT, but no
clear data are available in humans [24]. It has been shown
that treatment of mice with exogenous G-CSF induces MDSCs
that upon adoptive transfer into secondary recipients can
suppress GVHD [25]. In humans, a single study indicated that
the frequency of monocitic MDSC was signiﬁcantly increased
after allo-HSCT, especially in patients with aGVHD [9]. A
signiﬁcant correlation between the levels of MDSCs and the
concentration of G-CSF, IL-6, and IL-10 in the sera of patients
was also found [9], in line with the idea that the common
denominator of the accumulation of MDSCs is a driving in-
ﬂammatory milieu [24,26]. These cytokines, as well as
MDSCs, declined steadily over time after a peak that occurred
early after allo-HSCT [9]. In view of the developing opinion
that MDSCs regulate alloreactivity after transplantation and
that G-CSF stimulates the accumulation of MDSCs in vitro
[26] and in vivo [4], we explored the effect of G-CSFebased
mobilization regimens on MDSC phenotype, function, andTable 3
Variables from the Multivariate Analysis Describing the Probability of
Developing aGVHD
Variables Odds Ratio 95% Conﬁdence Interval P
HLA mismatches 1.52 .15-15.06 .72
Sex mismatch 0.93 .08-10.55 .95
Conditioning regimen 1.29 .15-11.05 .81
CD34þ cells 3.19 .47-21.55 .234
CD3þ cells 2.71 .44-16.56 .28
CD4þ cells 2.45 .24-25.04 .44
CD16/CD56þ cells .34 .07-1.62 .17
M-MDSC cells .10 .02-.486 .04
Results from the multivariate analysis with a backward-stepping procedure
that included all the variables with a P .5 in class comparison analyses. M-
MDSCs were the only factor signiﬁcantly associated with aGVHD occurrence
(P ¼ .04).
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CSFemobilized PBSC grafts on aGVHD.
By studying a larger cohort than in the previous report [4]
and in analogy with data in mice indicating that mouse bone
marrow cells cultured with G-CSF and GM-CSF resulted in
the generation of CD11bþGr1þ MDSCs able to suppress both
CD4þ and CD8þ alloresponse in vitro [8,25], we conﬁrmed
that systemic treatment with G-CSF induces an expansion of
myeloid cells displaying the phenotype of M-MDSCs (Linlow/
negHLA-DRCD11bþCD33þCD14þ). Because describing an
aberrant myeloid phenotype is not sufﬁcient for deﬁning
MDSCs, we demonstrated that the puriﬁed M-MDSCs have
the ability to suppress alloreactive T cell responses in vitro
and therefore meets the deﬁnition of MDSC. In allogeneic
HSCT, exogenous MDSCs alleviate GVHD in mice [8]; there-
fore, we reasoned that the M-MDSC graft dose might impact
on aGVHD and manipulating MDSCs may be a promising
therapeutic strategy. Indeed, we demonstrated that the
incidence of aGVHD was reduced when higher levels of
M-MDSCs were present among the infused donor cells. Even
when the age of the donor or recipient, gender, and HLA
mismatches were taken into account, the level of infused M-
MDSCs was the only signiﬁcant predictor of aGVHD (P ¼ .02,
Mann-Whitney t-test and P ¼ .04 multivariate analysis).
In clinical studies, the use of G-CSFemobilized peripheral
blood as a stem cell source is associated with enhanced GVT
effects without ampliﬁcation of signiﬁcant aGVHD [27],
although there are still some concerns about the fact that it
could increase the risk of leukemogenesis acting on imma-
ture myeloid precursors [28]. The mechanism by which G-
CSF ameliorates GVHD still remains controversial, although it
is known that G-CSF can induce a T helper 2 (TH2) polari-
zation of donor T cells while opposing T helper 1 differenti-
ation [29]. This TH2 polarization of the donor lymphocytes is
thought to down-regulate aGVHD, whereas on the other
hand it could be durable and could increase late infectious
complications [28]. In addition to direct effects of G-CSF on
donor T cell populations, additional data suggest that G-CSF
may reduce GVHD through effects on dendritic cells,
monocytes, NK cells, and NKT cells [30]. In in vitro studies
and experimental model systems, G-CSF was shown to pro-
mote the emergence of tolerogenic immature dendritic cell
subsets and granulocyte-monocyte precursors that dampen
allogeneic and mitogenic responses by recruiting regulatory
T cell populations [31]. Our results provide evidence of a new
mechanism bywhich G-CSFemobilized peripheral blood can
modulate aGVHD, supporting the hypothesis that G-CSF
directly affects regulatory M-MDSC frequencies in grafts fa-
voring the control of the alloreactivity of donor T cells in the
post-transplant period.
The mechanism of MDSC-induced GVHD protection re-
mains incompletely deﬁned. MDSCs suppressive functions
have been attributed to arginase-1, inducible nitric oxide
synthase, reactive oxygen species, and/or peroxynitrite
[8,32-34], indicating a fair level of discordance. The recently
published human study [9], analyzing MDSCs of the pheno-
type equivalent to the one we observed, revealed indole-
amine 2,3-dioxygenase as the key mediator of the
immunosuppressive activity of MDSCs in allo-HSCT. We
believe the presence of high level of MDSCs at the time of
transplantation is required to suppress T cell activation and
thus reduce GVHD development. In support of this hypoth-
esis, it has been shown that a rapid and signiﬁcant expansion
of MDSCs in peripheral lymphoid tissues of recipient mice
before receiving a Tcellereplete bonemarrowgraft led to theabrogation of aGVHD. Several studies reported that MDSCs
isolated in vivo from G-CSFetreated mice or MDSCs gener-
ated in vitro with various cytokines signiﬁcantly prevented
GVHD. On the other hand, MDSCs did not control ongoing
GVHD when given later than the activation and proliferation
of allogeneic T cells in vivo [25].
Because it is known that GVT responses depend on T cell
reactivity, it is reasonable to question whether increased
levels of M-MDSC also down-regulate GVT responses. Mu-
rine models have generated promising data in this sense,
demonstrating the adoptive transfer of MDSCs can result in
the successful control of GVHD without compromising GVT
effects [8,25]. Highﬁll et al. [8] demonstrated that in vitro
generated MDSCs migrate to the site of allo-priming, mainly
lymph nodes and spleen, shortly after transplantation and
suppress normal antigen presentation to alloreactive T cells.
Other reports focused on their ability to produce IL-10 and
induce IL-10 producing cells such as Tregs and different types
of antigen-presenting cells [31] or to suppress alloreactive T
cells through soluble secretion factor and direct cellecell
contact [1]. In our study no signiﬁcant correlation was found
between the number of G-CSFeinduced M-MDSCs and tu-
mor relapse or with transplant-related mortality. Likewise,
the 1-year overall survival and event-free survival rates were
not inﬂuenced by quantity of M-MDSCs infused at the
moment of transplantation. This is in line with MacDonald
et al. [31], who reported that G-CSFeinduced regulatory
myeloid cells, upon adoptive transfer, prevent GVHDwithout
compromising GVT in mice.
In patients undergoing allo-HSCT, other regulatory pop-
ulations present in PBSCs grafts such as Tregs and iNKT have
been demonstrated to correlate with aGVHD onset and grade
[13,22,23]. Nevertheless, in our study on a quite homogenous
population of patients receiving the same type of trans-
plantation (HLA compatibility, number of CD34þ and CD3þ
cells infused, conditioning regimen, and GVHD proﬁlaxis),
only M-MDSC graft levels are predictive of aGVHD. Stem cell
grafts with higher Tregs or iNKT content do not correlate
with less aGVHD. The discrepancy with previously published
reports might be due to several critical differences among
the studies, mainly type of transplantation, conditioning
regimen used, and study cohort. In addition, given the rela-
tively small sample size, our study might be underpowered
to detect the role of the analyzed parameters. The fact that in
such a cohort the M-MDSC graft content is the only variable
signiﬁcantly associated with aGVHD highlights the potential
key role of this cell population as an intrinsic antagonist of
GVHD. Whether other mobilizing agents affect M-MDSC
graft content is still not known but would be interesting to
assess. Plerixafor, for instance, might inﬂuence M-MDSCs by
binding to and blocking the chemokine receptor type 4
expressed on the cell surface as it does on stem cells, favoring
their migration in the bloodstream [35,36].
Although our data are determined in a relatively small
cohort and that further analyses in prospective studies are
required to validate the M-MDSC graft dose discriminating
patients at higher risk of developing aGVHD, our results
provide the proof of concept that MDSC-based approaches
might constitute a therapeutic option for aGVHD. Moreover,
given that MDSC levels can be modulated in vivo through
cytokines routinely used during stem cell mobilization
process, MDSCs therapies might be more feasible and less
expensive than expanding and manipulating other cellular
subsets such as Tregs and iNKT in vitro. In conclusion, our
report points to an important role of G-CSFeinduced
A. Vendramin et al. / Biol Blood Marrow Transplant 20 (2014) 2049e2055 2055M-MDSCs in suppressing aGVHD and will likely enhance
interest in developing clinical protocols aimed at modu-
lating G-CSF to affect M-MDSC graft cell doses to prevent a
GVHD.
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